Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis
✍ Scribed by G. Sroczynski; P. Schnell-Inderst; N. Mühlberger; K. Lang; P. Aidelsburger; J. Wasem; T. Mittendorf; J. Engel; P. Hillemanns; K.U. Petry; A. Krämer; U. Siebert
- Book ID
- 116430704
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 582 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
__Please cite this paper as:__ Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost‐effectiveness analysis. BJOG 2012;119:177–186. **Objective** To assess the cost
## Objective To determine the incremental costs and effects of different HPV testing strategies, when compared to Papanicolau cytology (Pap), for cervical cancer screening in Mexico. ## Methods A cost-effectiveness analysis (CEA) examined the specific costs and health outcomes associated with (1)